RNA-seq of four glioblastoma (GBM) cell lines treated with irradiation, PARP7i, diABZI alone or in combination with irradiation
Glioblastoma (GBM) is the deadliest type of brain cancer, exhibiting resistance not only to traditional treatments like radiation and chemotherapy but also to modern immunotherapy. GBM is classified as an immunologically cold tumor with an immunosuppressive microenvironment. Radio- and chemotherapy have been shown to alter the tumor microenvironment and trigger an anti-tumor immune response in various cancers, including breast, lung, and colorectal cancer, via the cGAS/STING and type I interferon (IFN-I) pathway. Additionally, STING agonists and inhibitors of DNA damage response and cell cycle checkpoints, which promote the accumulation of immunostimulatory cytoplasmic dsDNA, have been found to enhance the effects of radiation. Here we examined the immunogenic response of four different GBM cell lines (U251, T98G, GB-1, KALS-1) exposed to hypofractionated X-ray radiation (3x8 Gy) in combination with a STING agonist or with inhibitors targeting immune signaling (PARP7). We performed RNA-seq analysis of all four GBM cell lines treated with 3x8 Gy, PARP7i, diABZI alone or in combination with 3x8 Gy.